These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9120913)

  • 1. P53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer.
    Raitanen MP; Tammela TL; Kallioinen M; Isola J
    J Urol; 1997 Apr; 157(4):1250-3. PubMed ID: 9120913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 and RB expression predict progression in T1 bladder cancer.
    Grossman HB; Liebert M; Antelo M; Dinney CP; Hu SX; Palmer JL; Benedict WF
    Clin Cancer Res; 1998 Apr; 4(4):829-34. PubMed ID: 9563875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Grade progression and regression in recurrent urothelial cancer.
    Borhan A; Reeder JE; O'Connell MJ; Wright KO; Wheeless LL; di Sant'Agnese PA; McNally ML; Messing EM
    J Urol; 2003 Jun; 169(6):2106-9. PubMed ID: 12771728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
    Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
    Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
    Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ
    J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
    Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
    J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma.
    Bernardini S; Billerey C; Martin M; Adessi GL; Wallerand H; Bittard H
    J Urol; 2001 Jan; 165(1):42-6; discussion 46. PubMed ID: 11125360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder.
    Fleshner N; Kapusta L; Ezer D; Herschorn S; Klotz L
    J Urol; 2000 Oct; 164(4):1177-82. PubMed ID: 10992361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deoxyribonucleic acid ploidy and the clinical pattern of grade 2 superficial bladder cancer.
    Neulander E; Kaneti J; Chaimovitz C; Sion-Vardy N; Douvdevani A
    J Urol; 1997 Apr; 157(4):1254-8; discussion 1258-9. PubMed ID: 9120914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer.
    Pycha A; Mian C; Haitel A; Hofbauer J; Wiener H; Marberger M
    J Urol; 1997 Jun; 157(6):2116-9. PubMed ID: 9146595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of p53 nuclear accumulation in low- and high-grade (WHO/ISUP classification) transitional papillary carcinomas of the bladder for tumor recurrence and progression.
    Vardar E; Gunlusoy B; Minareci S; Postaci H; Ayder AR
    Urol Int; 2006; 77(1):27-33. PubMed ID: 16825812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
    J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.